Drug Profile
Research programme: neuropathic pain therpaeutic - Jeil Pharmaceuticals
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Neuropathic-pain in South Korea
- 21 Mar 2016 Early research in Neuropathic pain in South Korea prior to March 2016 (unspecified route)